Not Signed In -
Imiquimod |
Aldara |
Clinical Trial: 1-Year Follow up to the 1473-IMIQ Study
This study is currently recruiting patients.
|
Purpose
A 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ Study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.
| Condition | Intervention | Phase |
|---|---|---|
| Keratosis | Drug: Imiquimod 5% cream | Phase III |
MedlinePlus related topics: Skin Diseases
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study
Official Title: A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year after Completion of the 1473-IMIQ Study
Further Study Details:
Expected Total Enrollment: 84
Study start: January 2005; Expected completion: January 2006
Last follow-up: July 2005; Data entry closure: August 2005
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Subject had to participate in the 1473-IMIQ Study AND have had 100% clearance of AK lesions
Exclusion Criteria:
- Did not use any topical preparations in the previous treatment area within 24-hours of the scheduled visit.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00114023
Oregon
Dr. Robert Matheson, Portland, Oregon, 97223, United States; Recruiting
Jennifer Logan 503-245-1525
Robert Matheson, MD, Principal Investigator
Robert Matheson, MD, Principal Investigator
More Information
Study ID Numbers: 1518-IMIQ
Record last reviewed: June 2005
Last Updated: June 13, 2005
Record first received: June 13, 2005
ClinicalTrials.gov Identifier: NCT00114023
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-06-21
Record last reviewed: June 2005
Last Updated: June 13, 2005
Record first received: June 13, 2005
ClinicalTrials.gov Identifier: NCT00114023
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-06-21
email this page
print this page
bookmark this page
feedback on this page
